ArticleNeurology2020
Association of caffeine and related analytes with resistance to Parkinson disease among
Open access · hybridAbstract read
In one paragraph
Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Omics research in Parkinson's disease: evolution, integrated analysis, pathogenic mechanisms, biomarkers, and therapeutic targets.Frontiers in molecular neuroscience · 2026Pooled it
- Lifestyle medicine for neuroprotection: evidence and implementation in Asian contexts.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Multi-locus genetic dosage shapes cognitive disease progression in Parkinson's patients: 15-year meta-analysis of 24 cohorts.NPJ Parkinson's disease · 2026Article
- Plasma Levels of Food-Derived Metabolites as Biomarkers of Parkinson's Disease.International journal of molecular sciences · 2025Article
- LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.Molecular neurodegeneration · 2025Article
- Longitudinal assessment of the association between pesticide exposure and lifestyle with Parkinson's disease motor severity.NPJ Parkinson's disease · 2025Article
- Coffee Consumption Is Associated With Later Age-at-Onset of Parkinson's Disease.Annals of clinical and translational neurology · 2025Article
- Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.BMC neuroscience · 2025Article
- Metabolomics Unveils Disrupted Pathways in Parkinson's Disease: Toward Biomarker-Based Diagnosis.ACS chemical neuroscience · 2024Article
- Simulated LC-MS Data Set for Assessing the Metabolomics Data Processing Pipeline Implemented into MVAPACK.Analytical chemistry · 2024Article
- Selective dopaminergic neurotoxicity modulated by inherent cell-type specific neurobiology.Neurotoxicology · 2024Review
- Identification of metabolites reproducibly associated with Parkinson's Disease via meta-analysis and computational modelling.NPJ Parkinson's disease · 2024Article
- Epidemiology of Parkinson's Disease: An Update.Current neurology and neuroscience reports · 2024Review
- Article
- Targeting the adenosine AChinese journal of traumatology = Zhonghua chuang shang za zhi · 2024Review
- Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.Research square · 2024Article
- High-Throughput Lipidomic and Metabolomic Profiling for Brain Tissue and Biofluid Samples in Neurodegenerative Disorders.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Perspectives of People At-Risk on Parkinson's Prevention Research.Journal of Parkinson's disease · 2024Review
- Parkinson's Disease is Predominantly a Genetic Disease.Journal of Parkinson's disease · 2024Review
- The Role of Diet in Parkinson's Disease.Journal of Parkinson's disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Grace F CrottyFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA. grace.crotty@mgh.harvard.edu.
Romeo MaciucaFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Eric A MacklinFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Junhua WangFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Manuel MontalbanFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Sonnet S DavisFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Jamal I AlkabshFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Rachit BakshiFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Xiqun ChenFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Alberto AscherioFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Giuseppe AstaritaFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Sarah Huntwork-RodriguezFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Michael A SchwarzschildFrom the Department of Neurology (G.F.C., R.B., X.C., M.A.S.) and Biostatistics Center, Department of Medicine (E.A.M.), Massachusetts General Hospital; Harvard Medical School (G.F.C., E.A.M., R.B., X.C., A.A., M.A.S.), Boston, MA; Denali Therapeutics Inc. (R.M., J.W., M.M., S.S.D., J.I.A., G.A., S.H.-R.), San Francisco, CA; and Department of Nutrition (A.A.), Harvard T. H. Chan School of Public Health, Boston, MA.
Denali Therapeutics (United States) · USHarvard University · US
Funding
Urate-LRRK2 interactions in Parkinson's diseaseR01NS110879 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SCHWARZSCHILD, MICHAEL A · 2019 to 2023
$2.0MMC1R Basis of Melanoma-Parkinson's Link and Neuroprotective Potential of MC1RR01NS102735 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2018 to 2022
$1.8MNeuroprotection by MC1R as the basis for the melanoma-Parkinson's disease linkR21NS090246 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, XIQUN · 2015 to 2016
$450kNINDS NIH HHS R01 NS102735NINDS NIH HHS R01 NS110879NINDS NIH HHS R21 NS090246
Abstract
objectiveTo identify markers of resistance to developing Parkinson disease (PD) among
methodsPlasma from 368 patients with PD and UC in the LRRK2 Cohort Consortium (LCC), comprising 118
resultsPlasma caffeine concentration was lower in patients with PD vs UC (
conclusionsMetabolomic analyses of the LCC samples identified caffeine, its demethylation metabolites, and trigonelline as prominent markers of resistance to PD linked to pathogenic
Indexed as
AgedAlkaloidsCaffeineChromatography, LiquidCohort StudiesFemaleHeterozygoteHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MaleMass SpectrometryMetabolomicsMiddle AgedNeuroprotective AgentsParkinson DiseaseTheophylline1,7-dimethylxanthine1-methylxanthineAlkaloidsCaffeineLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanNeuroprotective AgentsTheophyllinetrigonellineXanthines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.